Home > Research > Publications & Outputs > Galantamine inhibits β-amyloid aggregation and ...
View graph of relations

Galantamine inhibits β-amyloid aggregation and cytotoxicity

Research output: Contribution to Journal/MagazineJournal articlepeer-review

<mark>Journal publication date</mark>15/05/2009
<mark>Journal</mark>Journal of the Neurological Sciences
Issue number1-2
Number of pages10
Pages (from-to)49-58
Publication StatusPublished
<mark>Original language</mark>English


The ability of galantamine (Reminyl) to inhibit the aggregation and toxicity of the beta-amyloid peptide (Abeta) was investigated. Galantamine showed concentration-dependent inhibition of aggregation of both Abeta 1-40 and Abeta 1-42, as determined by an ELISA method. Electron microscope studies of Abeta 1-40 incubated in the presence of galantamine revealed fibrils that were disordered and clumped in appearance. MTT and lactate dehydrogenase assays, employing SH-SY5Y human neuroblastoma cells, showed that galantamine reduced the cytotoxicity induced by Abeta 1-40. Galantamine also dramatically reduced Abeta 1-40-induced cellular apoptosis in these cells. There is some evidence that galantamine may not be acting purely as a symptomatic treatment. Disease-modifying effects of the drug could be due to an additional effect on Abeta aggregation and/or toxicity.